As a member of the MORL’s clinical team, my primary role is performing assays for the quantification of complement proteins (C3a, C3d, factor B, factor H, factor I, and soluble C5b-9) as well as overall pathway function. My current research studies the pharmacodynamic effects and efficacy of novel complement inhibitors in patients with C3G. In the future, I look forward to learning new experimental techniques and furthering my understanding of complement-mediated diseases.